New mastitis tube introduced by Boehringer Ingelheim Animal Health - Veterinary Practice
Your browser is out-of-date!

Update your browser to view this website correctly. Update my browser now

×

New mastitis tube introduced by Boehringer Ingelheim Animal Health

Ubropen is an intramammary suspension containing 600mg of Procaine penicillin

Ubropen is a new addition to Boehringer Ingelheim Animal Health’s Ubrocare range of mastitis products and is an intramammary suspension containing 600mg of Procaine penicillin. Featuring optimised dosing and composition, Ubropen harnesses the proven power of penicillin to allow targeted treatment of penicillin-sensitive gram positive mastitis pathogens. It also has the added benefit of three-five days on-label treatment options and the convenience of not needing to be stored in a refrigerator.

The 600mg dose results in a concentration well above MICs for Strep. uberis and Staph. aureusfor 24 hours, even after milking, which means it only needs to be administered once a day. Its formulation, consisting of mirconised particles in an oily base, enables optimum distribution of penicillin throughout all regions of the udder.

“Traditionally, in the UK, we have favoured broad spectrum mastitis therapy as our first line approach, however in many other European countries, including The Netherlands, Belgium, Sweden and Denmark, penicillin is the treatment of choice,” says Kath Aplin veterinary adviser at Boehringer Ingelheim Animal Health.

“For farms with a mixed or unknown mastitis pattern, the traditional broad spectrum approach to mastitis therapy makes sense,” she goes on to explain. “However, many vets now have a good knowledge of common mastitis pathogens on clients’ farms and, for those where gram positive pathogens predominate, penicillin as a first line treatment is well worth considering.”

In a field trial assessing the prevalence of mastitis-causing pathogens and clinical cure rates after treatment with Ubropen, mild and moderate cases of mastitis were treated for three to five day, with the causal pathogen being unknown at the time of treatment.

“In 80 percent of cases of grade one or two clinical mastitis, the causative pathogen was found to be gram positive and, following treatment with Ubropen, the overall clinical cure rate was 81 percent,” explains Ms Aplin.

Ubropen is now available from the usual veterinary wholesalers in boxes of 20 tubes.

References

Abbeloos, E., Pyörälä, S., Rajala‐Schultz P. and Myllys, V.

2018

Determination of the intramammary dose of benzylpenicillin required to maintain an adequate concentration in the milk to inhibit gram positive bacteria in the clinically normal udder for 24 hr. Journal of Veterinary Pharmacology and Therapeutics, 41, 691–698

Ehinger, A.M. and Kietzmann, M.

2000

Tissue distribution of benzylpenicillin after intramammary administration in the isolated perfused bovine udder. Journal of Veterinary Pharmacology and Therapeutics, 23, 303–310

Driess, M. and van Werven, T.

2019

Field trial to motivate and support Dutch farmers to treat grade 1 and 2 mastitis more prudent. Proceedings of the IDF Mastitis Conference – poster

Veterinary Practice

Improve Veterinary Practice (part of the Improve International Group) is an online knowledge and information hub for veterinary professionals across all specialties. It provides reliable, useful and interesting content, written by expert authors and covering small animal, large animal, exotics, equine and practice management
sectors of the veterinary surgeon and nursing professions.

Improve Veterinary Practice also offers a subscription-based membership, offering CPD courses and much more for the whole veterinary community.

Improve Veterinary Practice exists to inspire and inform your day-to-day work, and enable your ongoing professional development.


More from this author

Have you heard about our
IVP Membership?

A wide range of veterinary CPD and resources by leading veterinary professionals.

Stress-free CPD tracking and certification, you’ll wonder how you coped without it.

Discover more